Hospira Inc. Securities Fraud Lawsuit

Gilman Law LLP, a leading national securities law firm, is now accepting claims for lawsuits on behalf of Hospira, Inc. (“Hospira”) shareholders. The firm is actively investigating investor claims that Hospira, Inc. and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing false and misleading statements that caused Hospira’s stock to trade at artificially inflated prices. The firm is currently offering free legal evaluations to all Hospira investors nationwide.

For over 30 years, Gilman Law has represented investors in all major aspects of securities fraud litigation, including stock manipulation, securities fraud, and shareholder rights violations. If you purchased or otherwise acquired shares of Hospira (NYSE: HSP) between March 24, 2009 and October 17, 2011 (“Class Period”), and either lost money on the transaction or still hold the shares, you must contact Gilman Law LLP by January 20, 2012 (“Class Period”) to exercise your rights against Hospira Inc.

Hospira Inc. Class Action Lawsuit Allegations

Hospira is a global specialty pharmaceutical and medication delivery company that focuses on injectable drugs and infusion technologies. On October 18, 2011, Hospira announced disappointing preliminary third quarter financial results and slashed full-year guidance, pointing to a production disruption at its Rocky Mount, North Carolina plant, which accounted for approximately 25% of the Company’s sales. Hospira blamed the production slowdown at the North Carolina plant on the impact of an ongoing FDA investigation. On this news, Hospira stock plummeted $7.85 to close at $29.51 per share.

A lawsuit was subsequently filed in U.S. District Court for the Northern District of Illinois on behalf of purchasers of the common stock of Hospira, Inc. between March 24, 2009, and October 17, 2011. The complaint alleges that the Defendants failed to disclose that:

• Hospira suffered from extensive quality control issues, which undermined both the viability of and the supposed financial savings that would be generated by Project Fuel, a Company program designed to optimize Hospira’s operations and increase shareholder value;
• Hospira was unable to remedy problems identified in FDA Warning Letters related to Hospira’s infusion pumps, quality control deficiencies, and manufacturing weaknesses;
• Hospira’s revenue guidance for 2010 and 2011 was misstated;

As a result, defendants’ statements regarding Hospira’s final condition and expected earnings were false.

The complaint further alleges that the Defendants false statements caused Hospira’s stock to trade at artificially inflated prices during the Class Period.

Legal Help for Hospira Inc. Shareholders

Gilman Law has extensive experience representing both individual and institutional investors in securities class action suits, and has recovered over a billion dollars for its clients. We are ready to assist investors who have sustained losses as a result of Hospira Inc.’s fraudulent practices. For a free evaluation of your case or to obtain additional information, please fill out the form on the left or CALL TOLL FREE (888) 252-0048.